SUNESIS PHARMACEUTICALS Forum: Community User: Parisi

Geht das so weiter, erfolgt ein Delisting!

Chapeau

Naja notfalls immer über die Homepage 😂

https://seekingalpha.com/news/3611146-sunesis-pharmaceuticals-to-reverse-split-shares-1-10?utm_source=mystocksportfolio.app&utm_medium=referral

@Warren wo hast du die Info gestern Abend gefunden?

Danke!

Reverse Split 1:10

Wow die 30% gingen jetzt fix hab ich was verpasst? - bin nicht mehr drin, seit einiger Zeit schon zu riskant für mich.

Was meinst du damit warren?

Knackiger RS kommt

Geht jetzt erstmal wieder runter

Hab jetzt mal ein wenig gelesen was so läuft. Ziemlich interessant aber natürlich auch risiko reich. Bin noch unsicher klein zu investieren

Irgendwas läuft hier. Schulden bezahlt, angeblich hohes Management gefeuert. Alle setzen auf den Buyout

👀

Überlege nun auch noch einzusteigen

Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights Sunesis Pharmaceuticals, Inc. August 4, 2020, 1:00 pm SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2020. The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (International) and entering passcode 3484194. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com/events-and-presentations/upcoming-events. The webcast will be recorded and available for replay on the company's website for two weeks. About Sunesis Pharmaceuticals Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510 and its oral non-covalent BTK inhibitor vecabrutinib. SNS-510 is in IND-enabling studies and vecabrutinib is completing a Phase 1b trial in patients with advanced B cell malignancies.